Believe the Patient: How Diagnosis and Dismissal Shape Everything That Follows

Executive summary

Ebonie Michelle and Barry Nelson’s stories expose an early diagnostic pathway failure that biopharma teams feel downstream in trials, evidence, and access: when patients are dismissed early, options narrow fast. The opportunity is not “system overhaul.” It’s designing programs and partnerships that reduce predictable breakdowns at the moments that matter most.

What’s at stake for patients and programs

Advancement in precision oncology is moving quickly. Advancement in the patient journey often is not. Patients still hit the same early friction points: incomplete workups, delayed diagnosis, inconsistent guidance, and blatant suggestion that their concerns are not credible. The failures are system-wide, but they also become biopharma risks. They shape who reaches specialty care in time, who is offered clinical trials, and how defensible real-world outcomes look after launch.

This installment in Lumanity’s Patient Progress Series draws from the “Patient-Centric Innovations” session at Cancer Progress 2026 in New York City. The message from the stage was direct: patient-centric innovation begins before treatment selection. It begins when the system chooses whether to take the patient seriously.

Start where the cancer pathway begins

Ebonie Michelle framed the core requirement in one line:

“You may be the experts in cancer, but we are the experts in our bodies.”

If the system treats patient-reported signals as optional context, the pathway becomes fragile from the beginning. Patients lose time and opportunities they can’t get back, and that loss narrows options fast.

Ebonie described finding a lump in her breast and then raising concern about pain she felt on the other side. She was told, “cancer doesn’t hurt,” and even that it could be “sympathy pain.” That dismissal did not just feel wrong, it pushed her to take a specific action earlier than she otherwise would have: she sought a second opinion. At the second institution, she learned she had cancer on the other side as well, with different biology across sides.

Her takeaway: physicians may be experts in cancer, but patients are experts in their bodies. Patient-centric care starts when both are treated as true.

Barry Nelson’s lived experience highlights the same key moment from a different angle. Diagnosed with advanced non-small cell lung cancer, he described diagnostic coordination that worked early on: a primary care physician who moved quickly, scheduled scans, and orchestrated specialist appointments so he had a diagnosis within a week. Many patients never experience that kind of time-to-clarity.

Then he described what happened when he tried to align his care plan across his multidisciplinary care team. The response from a primary oncologist was:

“You’re gonna die, you need to accept it, this is a waste of our time.”

Barry left that institution and asked to see another lung cancer specialist. Ultimately, he moved his care. At the second cancer center, he heard a different sentence, one that changed the trajectory of his clinical pathway:

“We’ve got plenty of tools in the toolkit. And we’re going to fight as hard as you fight.”

At the first center, the care plan was essentially fixed and Barry’s needs were dismissed. At the second center, the team listened to Barry’s needs and coordinated a care plan to support him. In Barry’s case, that shift manifested quickly in access to a research team and clinical trials that hadn’t been discussed before.

Why this matters for biopharma

Biopharma cannot easily influence clinical culture, nor should it try to. But biopharma does rely on clinical pathways behaving in predictable ways. When early pathways break, three downstream effects show up repeatedly:

Options narrow before patients ever consider them. Ebonie’s experience is a reminder that a missed or dismissed signal early can change the biology you treat, the therapies you select, and the decisions the patient faces. Listen to Ebonie’s experience of being diagnosed with a second cancer:

Trial participation becomes a pathway problem. Barry described arriving at the second center where a clinical research team was integrated into care. He was not just seeing infusion nurses; he was also meeting with research staff who reviewed his case, what treatments were in development, and what trials might be available to him. That is not a brochure. That is an operating model. Listen to Barry’s experience of a research center with an integrated care team:

Innovation is judged by lived experience, not scientific novelty. Barry described a trial experience where side effects were severe enough that he lost equilibrium while driving and later had to crawl up the stairs to his home. For patients, the difference between “progress” and “punishment” can be tolerability and daily function. That difference also shapes persistence and real-world outcomes. Listen to Barry’s experience of side effects caused by a clinical trial treatment:

Clarity is a design choice, not a personality trait

Ebonie shared a small exchange that captures a big pattern. After diagnostic imaging, when she asked what was seen on her film, she was told:

“Ah, it’s really technical, you don’t have to worry about it”

Her response was pointed:

“I have a master’s in public health, how about you try me?“

Most patients will not respond that way, even if they want to. That is the point. A diagnostic process that requires confidence, education, and confrontation to get clarity is not patient-centric. It rewards the boldest voices, not the greatest need.

This is also where “patient-centric” connects to evidence and access. If patients do not understand what is happening and why, they struggle to navigate options, adhere to complex regimens, or participate in research. The proof package gets harder to defend, not because the asset lacks value, but because the pathway is inconsistent.

A human connection that should be more normal in our industry

Barry described a moment after he entered an immunotherapy trial when a scientist involved in developing the therapy came to his appointment, reviewed scans, and reacted to the impact:

“Oh my God, your tumor shrunk 25%“

The scientist invited Barry to the lab so the team could see the patient impact of their work. It is a powerful image of what the ecosystem can be when it is connected.

For biopharma leaders, this is not just a nice story. It is a reminder that “patient voice” stops being a tagline and becomes an input into concrete choices: what to optimize next, what support needs to be engineered around the therapy, and what evidence will be credible beyond response rates.

Biopharma levers, one program at a time

You cannot rebuild the entrance door to the oncology pathway across all medical institutions and oncology sites. You can reduce predictable breakdowns across the sites, partners, and workflows your program touches:

• Build decision-ready clarity into patient-facing and site-facing materials so understanding does not depend on education level or confidence
• Treat early option evaluation as a design requirement, including trial consideration workflows that occur before treatment decisions foreclose eligibility
• Select and support sites for consistency and patient experience, not only enrollment speed
• Design your evidence plan to survive real-world pathway variation, including outcomes that reflect function and lived experience, not only tumor response

The takeaway for biopharma

Ebonie and Barry did not ask the field for sentiment. They asked for operational respect: complete workups, clear explanations, aligned teams, and access to options early enough to matter. For biopharma, the opportunity is practical. Treat diagnostic variability and dismissal as known failure modes that can be reduced program by program. That is how “believe the patient” becomes a pathway that holds up under scrutiny.